Angiogenesis: General mechanisms and implications for rheumatoid arthritis;Angiogenèse: Mécanismes généraux et implications au cours de la polyarthrite rhumatoïde

Revue du Rhumatisme (Edition Francaise)

Volumn 67, Issue 8, 2000, Pages 573-592

  Weber, Anne Joëlle ^a   De Bandt, Michel ^a  

^a Section of Radiology   (France)

Author keywords

Angiogenesis; Angiogen se; Endothelium; Endoth lium; Hypoxia; Hypoxie; Integrins; Int grines; Metalloproteinases; M talloprot ases; Polyarthrite rhumato de; Rheumatoid arthritis

Indexed keywords

EID: 0042412287     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1169-8330(00)00015-6     Document Type: Review

References (127)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1. 1:1995;27-31.
2. Cramer D.A. Applied vascular biology: can angiogenesis inhibitors help control malignant growth? Ann Intern M. 129:1998;841-844.
3. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs. 58:1999;17-38.
4. Ferrante K., Winograd B., Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol. 43:(Suppl):1999;61-68.
5. Ferrara N. Missing link in angiogenesis. Nature. 376:1995;467-467.
6. Denekamp J. Angiogenesis, neovascular proliferation and vascular physiopathology as targets for cancer therapy. Br J Radiol. 66:1993;181-196.
7. Koch A.E. Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum. 41:1998;951-962.
8. Firestein G.S. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors. Arthritis Rheum. 39:1996;1781-1790.
9. Lioté F. Angiogenèse synoviale. Sèze S de, Ryckewaert A, Kahn M.F, Kuntz D, Guérin C. L'Actualité rhumatologique présentée au praticien. 1990;233-243 Expansion Scientifique Française, Paris.
10. Lioté F. Cellules endothéliales et inflammation synoviale. Sèze S de, Ryckewaert A, Kahn M.F, Kuntz D, Dryll A, Guérin C. L'Actualité rhumatologique présentée au praticien. 1991;303-312 Expansion Scientifique Française, Paris.
11. Hirohata S., Sakakibara J. Angiogenesis as a possible elusive triggering factor in rheumatoid arthritis. Lancet. 353:1999;1331-c.
12. Le Loët X., Daragon A., Tron F. La polyarthrite rhumatoïde « très récente »: pourquoi et comment l'étudier ? Rev Rhum [Éd Fr]. 63:1996;549-552.
13. Koch A.E., Halloran M.M., CJ Haskell, MR Shah, PJ Polverini. Angiogenesis mediated by soluble forms of E-selectine and vascular cell adhesion molecule-1. Nature. 376:1995;517-519.
14. Blake D.R., Merry P., Unsworth J., Kidd B.L., Outhwaite J.M., Ballard R., et al. Hypoxic-reperfusion injury in the inflamed human joint. Lancet. 8633:1989;289-292.
15. Levick J.R. Hypoxia and acidosis in chronic inflammatory arthritis; relation to vascular supply and dynamic effusion pressure. J Rheumatol. 17:1990;579-582.
16. Walsh D.A. Angiogenesis and arthritis. Rheumatology. 38:1999;103-112.
17. Walsh D.A., Wade M., Mapp P.I., Blake D.R. Focally regulated endothelial proliferation and cell death in human synovium. Am J Pathol. 152:1998;691-702.
18. Ceponis A., Konttinen Y.T., Imai S., Tamulaitiene M., Li T.F., Xu J.W., et al. Synovial lining, endothelial and inflammatory mononuclear cell proliferation in synovial membranes in psoriasic and reactive arthritis: a comparative quantitative morphometric study. Br J Rheumatol. 37:1998;170-178.
19. Mapp P.I., Kidd B.L., Gibson S.J., Terry J.M., Revell P.A., Ibrahim N.B., et al. Substance P-, calcitonin gene-related peptide- and C-flanking peptide of neuropeptide Y-immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis. Neuroscience. 37:1990;143-153.
20. Paleolog E.M. Angiogenesis: a critical process in pathogenesis of RA. A role for VEGF ? Br J Rheumatol. 35:1996;917-918.
21. Koch A.E., Harlow L.A., Haines G.K., Amento E.P., Unemori E.N., Wong W.L., et al. Vascular endothelial growth factor, a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol. 152:1994;4149-4156.
22. Koch A.E., Polverini P.J., Kunkel S.L., Harlow L.A., DiPietro L.A., Elner V.M., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 258:1992;1798-1801.
23. Thomas K.A. VEGF, a potent and selective angiogenic agent. J Biol Chem. 271:1996;603-606.
24. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. VEGF and its receptors. FASEB J. 13:1999;9-22.
25. Gaudry M., Brégerie O., Andrieu V., El Benna J., Pocidalo M.A., Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood. 90:1997;4153-4161.
26. Fava R.A., Olsen N.J., Spencer-Green G., Yeo K.T., Yeo T.K., Berse B., et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp M. 180:1994;341-346.
27. Nagashima M., Yoshino S., Ishiwata T., Asano G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol. 22:1995;1624-1630.
28. Weber A.J., Grossin M., De Bandt M., Pocidalo M.A., Gaudry M. Le VEGF (Vascular Endothelial Growth Factor) est exprimé dans des arthrites rhumatoïdes destructrices et sévères: une étude immunohistochimique sur des synoviales humaines [résumé]. Rev Rhum [Éd Fr]. 42:1999;675-675.
29. Bikfalvi A., Klein S., Pintucci G., Rifkin D.B. Biological roles of fibroblast growth factor-2 (FGF2). Endocr Rev. 18:1997;26-45.
30. Qu Z., Huang X.N., Ahmadi P., Andresevic J., Planck S.R., Hart C.E., et al. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab Invest. 73:1995;339-346.
31. Schulze-Osthoff K., Risau W., Vollmer E., Sorg C. In situ detection of basic fibroblast growth factor by highly specific antibodies. Am J Pathol. 137:1990;85-92.
32. Nakashima M., Eguchi K., Aoyagi T., Yamashita I., Ida H., Sakai M., et al. Expression of basic fibroblast growth factor in synovial tissues from patients with rheumatoid arthritis: detection by immunohistological staining and in situ hybridisation. Ann Rheum Dis. 53:1994;45-50.
33. Tamura T., Nakanishi T., Kimura Y., Hattori T., Sasaki K., Norimatsu H., et al. Nitric oxyde mediates interleukin-1-induced matrix degradation and basic fibroblast growth factor release in cultured rabbit articular chondrocytes: a possible mechanism of pathological neovascularization in arthritis. Endocrinology. 137:1996;3729-3737.
34. Samaniego F., Markham P.D., Gendelman R., Watanabe Y., Kao V., Kowalski K., et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol. 152:1998;1433-1443.
35. Dickson M.C., Martin J.S., Cousins F.M., Kulkarni A.B., Karlsson S., Akhurst R.J. Defective hematopoiesis and vasculogenesis in transforming growth factor-β1 knock-out mice. Development. 121:1995;1845-1854.
36. Gleizes P.E., Rifkin D.B. L'activation du TGF-β latent, un mécanisme requis pour l'intégrité vasculaire. Pathol Biol. 4:1999;322-329.
37. Chu C.Q., Field M., Abney E., Zheng R.Q., Allard S., Feldmann M., et al. Transforming growth factor-beta 1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol. 86:1991;380-386.
38. Goddard D.H., Grossman S.L., Williams W.V., Weiner D.B., Gross J.L., Eidsvoog K. Regulation of synovial cell growth: coexpression of transforming growth factor β and basic fibroblast growth factor by cultured synovials cells. Arthritis Rheum. 35:1992;1296-1303.
39. Taketasu F., Kato M., Golb A., Ichijo H., Ten Djike P., Itoh J., et al. Enhanced expression of transforming growth factor-beta and transforming growth factor-beta type II receptor in the synovial tissues of patients with rheumatoid arthritis. Lab Invest. 70:1994;620-630.
40. Roberts A.B., Sporn M.B., Assoian R.K., Smith J.M., Roche N.S., Wakefield L.M., et al. Transforming growth factor type beta: rapid induction of fibrosis, and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 83:1986;4167-4171.
41. Colville-Nash P.R., Scott D.L. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis. 51:1992;919-925.
42. Shiozawa S., Shiozawa K., Tanaka Y., Morimoto I., Uchihashi, Fujita T., et al. Human epidermal growth factor for the stratification of synovial lining layer and neovascularisation in rheumatoid arthritis. Ann Rheum Dis. 48:1989;820-828.
43. Koch A.E., Halloran M.M., Hosaka S., Shah M.R., Haskell C.J., Baker S.K., et al. Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis. Arthritis Rheum. 39:1996;1566-1575.
44. Bussolino F., Di Renzo M.F., Ziche M., Bochietto E., Olivero M., Naldini L., et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell mobility and growth. J Cell Biol. 119:1992;629-641.
45. Bussolino F., Ziche M., Wang J.M., Alessi D., Morbidelli L., Cremona O., et al. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest. 87:1991;986-995.
46. Takeuchi M., Otsuka T., Matsui N., Asai K., Hirano T., Moriyama A., et al. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid arthritis. Arthritis Rheum. 37:1994;662-672.
47. Strieter R.M., Kunkel S.L., Elner V.M., Martonyi C.L., Koch A.E., Polverini P.J., et al. Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol. 141:1992;1279-1284.
48. Paleolog E. Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis. Mol Pathol. 50:1997;225-233.
49. Paleolog E.M., Young S., Stark A.C., McCloskey R.V., Feldmann M., Maini R.N. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 41:1998;1258-1265.
50. Jackson J.R., Minton J.A.L., Ho M.L., Wei N., Winkler J.D. Expression of VEGF in synovial fibroblasts is induced by hypoxia and interleukin-1β J Rheumatol. 24:1997;1253-1259.
51. Berse B., Hunt J.A., Diegel R.J., Morganelli P., Yeo K., Brown F., et al. Hypoxia augments cytokine (transforming growth factor beta (TGFβ) and IL-1)-induced VEGF secretion by human synovial fibroblasts. Clin Exp Immunol. 115:1999;176-182.
52. Badet J. Angiogenin, a potent mediator of angiogenesis: biological, biochemical and structural properties. Pathol Biol. 47:1999;345-351.
53. Hu G.F., Riordan J.F. Angiogenin enhances actin acceleration of plasminogen activation. Biochem Biophys Res Commun. 197:1993;682-687.
54. Hu G.F., Riordan J.F., Vallée B.L. Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci USA. 91:1994;12096-12100.
55. Hosaka S., Shah M.R., Barquin N., Haines G.K., Koch A.E. Expression of basic fibroblast growth factor and angiogenin in arthritis. Pathobiology. 63:1995;249-256.
56. Dobryszycka W. Biological functions of haptoglobin. New pieces to an old puzzle. Eur J Clin Chem Clin Biochem. 35:1997;647-654.
57. Cid M.C., Grant D.S., Hoffman G.S., Auerbach R., Fauci A.S., Kleinman H.K. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest. 91:1993;977-985.
58. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondine. Proc Natl Acad Sci USA. 87:1990;6624-6628.
59. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 265:1994;1582-1584.
60. Bagavandoss P., Wilks J.W. Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem Biophys Res commun. 170:1990;867-872.
61. Murphy-Ullrich J.E., Hook M. Thrombospondin modulates focal adhesions in endothelial cells. J Cell Biol. 109:1989;1309-1319.
62. Koch A.E., Szekanecz Z., Friedman J., Kenneth Haines G., Langman C.B., Bouck N.P. Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. Clin Immunol Immunopathol. 86:1998;199-208.
63. Maione T.E., Gray G.S., Petro J., Hunt A.J., Donner A.L., Bauer S.I., et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 247:1990;77-77.
64. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatine: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
65. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
66. Moses M.A., Sudhalter J., Langer R. Identification of neovascularization from cartilage. Science. 248:1990;1408-1410.
67. Moses M.A., Wiederschain D., Wu I., Fernandez C.A., Ghazizadeh V., Lane W.S., et al. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci USA. 96:1999;2645-2650.
68. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 87:1995;581-586.
69. Bucht A., Larsson P., Weisbrot L., Thorne C., Pisa P., Smedegard G., et al. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol. 103:1996;357-367.
70. Malfait A.M., Butler D.M., Presky D.H., Maini R.N., Brennan F.M., Feldmann M. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol. 111:1998;377-388.
71. Joosten L.A., Lubberts E., Helsen M.M., Van Den Berg W.B. Dual role of IL-12 in early and late stages of murine collagen type II arthritis. J Immunol. 159:1997;4094-4102.
72. Kasama T., Yamazaki J., Hanaoka R., Miwa Y., Hatano Y., Kobayashi K., et al. Biphasic regulation of the development of murine type II collagen-induced arthritis by interleukin-12: possible involvement of endogenous interleukin-10 and tumor necrosis factor alpha. Arthritis Rheum. 42:1999;100-109.
73. Sidky Y.A., Borden E.C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 47:1987;5155-5161.
74. Dohlain R.J., Ter Haar N.T., Hoefakker S., Tak P.P., De Ley M., Claasen E., et al. Increased expression of interferon (IFN)-gamma together with IFN-gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis. Br J Rheumatol. 35:1996;24-32.
75. Ricketts R.R., Hatley R.M., Corden B.J., Sabio H., Howell C.G. Interferon-alpha-2a for the treatement of complex hemangiomas of infancy and childhood. Ann Surg. 219:1994;605-612.
76. Weyrich A.S., McIntyre T.M., McEver R.P., Prescott S.M., Zimmerman G.A. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest. 95:1995;2297-2303.
77. Combe C., Duplaa C., Couffinhal T., Moreau C., Bonnet J. Induction of intercellular adhesion molecule-1 by monocyte adhesion to endothelial cells in human culture system. J Cell Physiol. 164:1995;295-303.
78. Nguyen M., Strubel N.A., Bischoff J. A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature. 365:1993;267-269.
79. Eliceiri B.P., Cheresh D.A. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 103:1999;1227-1230.
80. Clark E.A., Brugge J.S. Integrins and signal transduction pathways: the road taken. Science. 268:1995;233-239.
81. Leavesley D.I., Schwartz M.A., Rosenfeld M., Cheresh D.A. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol. 121:1993;163-170.
82. Friedlander M., Brooks P.C., Shaffer R.W., Kincaid C.M., Varner J.A., Cheresh D.A. Definition of two angiogenic pathways by distinct alpha integrins. Science. 270:1995;1500-1502.
83. Bader B.L., Rayburn H., Crowley D., Hynes R.O. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell. 95:1998;507-519.
84. Pirila L., Heino J. Altered integrin expression in rheumatoid synovial lining B cells: in vitro cytokine regulation of alpha 1 beta 1, alpha 6 beta 1 et alpha v beta 5 integrins. J Rheumatol. 23:1996;1691-1698.
85. 3antagonist. J Clin Invest. 103:1999;47-54.
86. Stupack D.G., Storgard C.M., Cheresh D.A. A role for angiogenesis in rheumatoid arthritis. Braz J Med Biol Res. 32:1999;573-581.
87. Neidhart M., Wehrli R., Bruhlmann P., Michel B.A., Gay R.E., Gay S. Synovial fluid CD146 (MUC18), a marker for synovial membrane angiogenesis in rheumatoid arthritis. Arthritis Rheum. 42:1999;622-630.
88. Brooks P.C., Montgomery A.M.P., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
89. Scatena M., Almeida M.L., Chaisson M.L., Fausto N., Nicosia R.F., Giachelli C.M. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol. 141:1998;1083-1093.
90. Stromblad S., Becker J.C., Yebra M., Brooks P.C., Cheresh D.A. Suppresion of p53 and p21WAF1/CIP1 expression by vascular cell integrin alpha v beta3 during angiogenesis. J Clin Invest. 98:1996;426-433.
91. Brooks P.C., Silletti S., Von Schalscha T.L., Friedlander M., Cheresh D.A. Disruption of angiogenesis by PEX, a non catalytic metalloproteinase fragment with integrin binding activity. Cell. 92:1998;391-400.
92. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 103:1999;1237-1241.
93. Cawston T. Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases. Mol Med Today. 4:1998;130-137.
94. Sang Q.X. Complex role of matrix metalloproteinases in angiogenesis. Cell Res. 8:1998;171-177.
95. Jackson J.J., Arkell J., Nguyen M. Rheumatoid synovial endothelial cells secrete decreased levels of tissue inhibitor of MMP (TIMP1). Ann Rheum Dis. 57:1998;158-161.
96. Jain R.K., Schlenger K., Höckel M., Yuan F. Quantitative angiogenesis assays: progress and problems. Nat M. 3:1997;1203-1208.
97. Crum R., Szabo S., Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 230:1985;1375-1378.
98. Kenyon B., Voest E.E., Chen C.C., Flynn E., Folkman J., D'Amato R. A model of angiogenesis in the mouse cornea. Invest Ophtalmol Vis Sci. 37:1996;1625-1632.
99. Passaniti A., Taylor R.M., Pili R., Guo Y., Long P.V., Haney J.A., et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest. 67:1992;519-527.
100. Bar-Ner M., Eldor A., Wasserman L., Matzner Y., Cohen I.R., Fuks Z., et al. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood. 70:1987;551-557.
101. Peacock D.J., Banquerido M.L., Brahn E. A novel angiogenesis inhibitor suppresses rat adjuvant arthritis. Cell Immunol. 160:1995;178-184.
102. Peacock D.J., Banquerigo M.L., Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp M. 175:1992;1135-1138.
103. Oliver S.J., Cheng T.P., Banquerigo M.L., Brahn E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combinaison with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol. 166:1995;196-206.
104. Oliver S.J., Banquerico M.L., Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, Taxol. Cell Immunol. 157:1994;291-299.
105. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., et al. Synthetic analogues of fumagillin inhibit angiogenesis and suppress tumor growth. Nature. 348:1990;55557-55557.
106. Sin N., Meng L., Wang M.Q.W., Wen J.J., Bornmann W.G., Crews C.M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA. 94:1997;6099-6103.
107. Kukasa M., Sudo K., Fujita T., Marui S., Itoh F., Ingberand D., et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun. 174:1991;1070-1076.
108. Shishido T., Yasoshima T., Denno R., Mukaiya M., Sato N., Hirata K. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combinaison with cisplatin. Jpn J Cancer Res. 89:1998;963-969.
109. Castronovo V., Belotti D. TNP 470 (AGM-1470): mechanisms of action and early clinical development. Eur J Cancer. 32A:1996;2520-2527.
110. Lider O., Baharav E., Mekori Y.A., Miller T., Naparstek Y., Vlodavsky I., et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest. 83:1989;752-756.
111. Oliver S.J., Cheng T.P., Banquerigo M.L., Brahn E. The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol. 25:1998;964-969.
112. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:1994;4082-4085.
113. De Bandt M., Grossin M., Weber A.J., Pla M., Chopin M., Pocidalo M., et al. Angiogenesis inhibitor suppresses arthritis and preserves from bone destruction in a new transgenic mouse model of RA. Arthritis Rheum. 9 Suppl:1999;118-118.
114. Kouskoff V., Korganow A.S., Duchatelle V., Degott C., Benoist C., Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell. 87:1996;811-822.
115. Nauck M., Karakiulakis G., Perruchoud A.P., Papakonstantinou E., Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 341:1998;309-315.
116. Nagashima M., Yoshino S., Aono H., Takai M., Sasano M. Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin Exp Immunol. 116:1999;360-365.
117. Iurlaro M., Vacca A., Minischetti M., Ribatti D., Pellegrino A., Sardanelli A., et al. Antiangiogenesis by cyclosporine. Exp Hematol. 26:1998;1215-1222.
118. Storogenko M., Pech-Amsellem M.A., Kerdine S., Rousselet F., Pallardy M. Cyclosporin-A inhibits human endothelial cells proliferation through interleukin-6-dependent mechanisms. Life Sci. 60:1997;1487-1496.
119. Madhok R., Wijelath E., Smith J., Watson J., Sturrock R.D., Capell H.A. Is the beneficial effect of sulfasalazine due to inhibition of synovial neovascularization ? J Rheumatol. 18:1991;199-202.
120. Hirata S., Matsubara T., Saura R., Tateishi H., Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum. 32:1989;1065-1073.
121. Koch A.E., Burrows J.C., Polverini P.J., Cho M., Leibovich S.J. Thiol-containing compounds inhibit the production of monocyte/macrophage-derived angiogenic activity. Agents Actions. 34:1991;350-357.
122. Matsubara T., Saura R., Hirohata K., Ziff M. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J Clin Invest. 83:1989;158-167.
123. Inyang A.L., Bikfalvi A., Lu H., Tobelem G. Chloroquine's modulation of endothelial cell activity induced with basic fibroblast growth factor and human serum: effect on mitogenesis, protease production and cell migration. Cell Biol Int Rep. 14:1990;35-46.
124. Tamargo R.J., Bok R.A., Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 51:1991;672-675.
125. Gilbertson-Beadling S., Powers E.A., Stamp-Cole M., Scott P.S., Wallace T.L., Copeland J., et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol. 36:1995;418-424.
126. Masferrer J.L., Koki A., Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci. 889:1999;84-86.
127. Thompson W.D., Li W.W., Maragoudakis M. The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel human therapies. J Pathol. 187:1999;503-510.